Ribonucleases and Immunoribonucleases as Potential Modalities of Anticancer Therapy

Download Citation in txt Download Citation in bib Download Citation in ris

Author Info

Monika Kowalik Magdalena Witkowska Piotr Smolewski

Corresponding Author

Piotr Smolewski
Department of Experimental Hematology, Medical University of Lodz, Poland

A B S T R A C T

A novel approach of antitumor treatment, that involves targeting RNA either using specific antisense oligonucleotides or cytostatic/cytotoxic ribonucleases (RNases), is being promoted. Among recently described cytotoxic RNases, amphibian RNases, including ranpirnase (onconase; ONC) and Amphinase (rAmph), are promising anticancer agents. They manifest strong antitumor effects and act synergistically with several cytostatics. Recently, rapidly developed proteins by engineering of RNases, displayed cytotoxic activity against several types of malignant cells. Most recent data show the role of microRNAs in mediating tumor progression, opening a new field of possible molecular targets for RNases. This review summarizes the current status of those RNases and immunoRNases as promising novel anticancer therapeutics.

Article Info

Article Type

Review Article

Publication history

Received: Tue 07, Jul 2020
Accepted: Wed 22, Jul 2020
Published: Thu 10, Sep 2020

Copyright

© 2023 Piotr Smolewski. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.DDA.2020.01.04